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Available online 12 November 2007Neural and mesenchymal stem cells have been proposed as alternative
sources of cells for transplantation into the brain in neurodegenerative
disorders. However, the endogenous factors controlling their engraft-
ment within the injured parenchyma remain ill-defined. Here, we
demonstrate significant engraftment of undifferentiated exogenous
mesenchymal or neural stem cells throughout the lesioned area in a rat
model for Huntington's disease, as late as 8 weeks post-transplanta-
tion. We show that stem cell factor (SCF), strongly up-regulated
within host cells in the damaged striatum, is able to activate the SCF
receptor c-kit and its signaling pathway and to promote the migration
and proliferation of mesenchymal and neural stem cells in vitro.
Furthermore, c-kit receptor blockade alters neural stem cell distribu-
tion within the lesioned striatum. Host SCF expression is observed in
atypical cells expressing glial fibrillary acidic protein and doublecortin
in the lesioned striatum and in migrating doublecortin-positive
progenitors. Taken together, these data demonstrate that SCF
produced in situ in the lesioned striatum is an important factor in
promoting the engraftment of stem cells within the lesioned brain.
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doi:10.1016/j.mcn.2007.11.001IntroductionStem cells are immature cells with the capacity for self-renewal
that display the ability to differentiate into multiple mature cell types
(Lindvall et al., 2004). The transplantation of stem cells or the
mobilization of endogenous stem cells within the injured adult brain
has been proposed as a potential therapy for neurological diseases
(for reviews see Isacson, 2003; Tai and Svendsen, 2004).
Huntington's disease (HD) is a fatal inherited neurodegenerative
disorder for which no treatment is yet available (Blum et al., 2003
and references herein). The transplantation of human fetal striatal
tissue might serve as a useful therapeutic strategy and has led to
encouraging results in clinical studies (Bachoud-Levi et al., 2000;
Peschanski et al., 2004; Bachoud-Levi et al., 2006). However, adult
stem cells such as mesenchymal stem cells (MSCs) and neural stem
cells (NSCs) represent an attractive alternative. Although much
information has been collected about the behavior and fate of fetal
cells grafted into HD models (Kendall et al., 1998; Palfi et al., 1998;
for reviews see Nakao and Itakura, 2000; Peschanski et al., 2004),
less is known about the potential of stem cell transplantation.
A few studies have shown that pre-differentiated neural stem
cells or growth factor-expressing stem cell lines confer behavioral
benefits and/or cellular protection in phenotypic models of HD
(Martinez-Serrano and Bjorklund, 1996; Kordower et al., 1997;
Bosch et al., 2004; Ryu et al., 2004; McBride et al., 2004). Recently,
it has also been demonstrated that environmental changes occurring
during HD or following quinolinic acid (QA)-induced striatal
lesions in a rat model reminiscent of HD (Beal et al., 1986; see also
Guidetti et al., 2004) may stimulate in situ neurogenesis (Curtis
et al., 2003; Tattersfield et al., 2004). Although the recruitment of
endogenous neural stem cells in response to injury is clearly
455K. Bantubungi et al. / Mol. Cell. Neurosci. 37 (2008) 454–470insufficient to compensate for progressive cell loss, it indicates that
factors supporting the survival of stem cells are present within the
lesioned area. However, the extent to which stem cells can migrate,
survive and/or proliferate within the injured striatum, as well as the
possible contribution of endogenous factors favoring their engraft-
ment, remain pending questions. One such factor could be the stem
cell factor (SCF), the ligand for the receptor c-kit. SCF has been
shown to be a mitogen and chemoattractant for many cells in the
hematopoietic system to enhance the mobilization of peripheralFig. 1. Culture, pre-staining and characterization of rMSCs and rNSCs before transp
(bone marrow of 12w adult rat) and rNSCs (ganglionic eminence of E17 embryos),
and rNSCs (Bb). (Ac and Bc) Typical fluorescent pre-graft staining following PKH
nestin (green) expression in pre-graft rMSCs (Ad) and rNSCs (Bd). Note that almos
using both polyclonal and monoclonal antibodies. (Ae) In vitro perinuclear loca
perinuclear localization of PKH26 labeling (red) in the striatum of a rat grafted with
in blue. (Be–g) Phenotype of rNSCs following in vitro differentiation. Cells expr
Be–g=20 μm, Ae–f=5 μm.blood progenitor cells (McNiece and Briddell, 1995; Glaspy, 1996)
and to play an important role in hematopoiesis, gametogenesis and
melanogenesis (Williams and Lyman, 1991). The role of SCF in the
nervous system is poorly understood. However, SCF has recently
been shown to stimulate neurogenesis as well as the migration of
endogenous neural progenitors in vivo (Jin et al., 2002; Sun et al.,
2004). These data support that SCF could be an important factor in
regulating the proliferation and recruitment of endogenous progeni-
tor cells during brain injury.lantation. (Aa and Ba) Schematic drawings representing the origin of rMSCs
respectively. (Ab and Bb) Typical phase contrast morphology of rMSCs (Ab)
26 labeling of rMSCs (Ac) and rNSCs (Bc). (Ad and Bd) GFAP (red) and
t all cells coexpressed both markers. Similar GFAP expression was observed
lization of PKH26 labeling in rMSCs before transplantation. (Af) In vivo
rMSCs and sacrificed 3 weeks later. TOTO-3 iodide counterstaining is shown
ess MAP2 (Be), GFAP (Bf) or CNPase (Bg). Scale bars: Ab–d, Bb–d and
Fig. 2. (A) Schematic drawing representing the experimental protocol used
for striatal lesions, stem cell transplantation and sacrifice of animals (ST:
short-term, i.e., 3 weeks following transplantation=4 weeks following QA
injection; LT: long-term, i.e., 8 weeks following transplantation=9 weeks
following QA injection). (B) Typical cytochrome oxidase histochemical
staining of striata injected with vehicle (left) or QA (right) 4 weeks after
surgery. Note the absence of cytochrome oxidase activity within the lesion
core after QA lesions as well as the striatal atrophy and ventricle
enlargement in the QA-lesioned section (right) when compared to the
control (left).
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nestin-positive MSCs and NSCs grafted into the striatum following
quinolinic acid (QA)-induced degeneration in a rat model of Hunt-
ington's disease. We observed that the pathological environment
favors the engraftment of both cell types throughout the lesion core
up to 2 months post-transplantation. The migration and/or proli-
feration of grafted cells within the degenerating striatum could
depend, at least in part, on SCF produced in situ by atypical host cells
expressing glial fibrillary acidic protein (GFAP), nestin and double-
cortin (DCX), as well as by neural progenitors that migrate from the
rostro-dorsal part of the subventricular zone (SVZ) to the lesion. Our
observations strongly support the conclusion that (1) the local
production of SCF by the host favors MSC or NSC engraftment
within the striatum and (2) pathology-induced host gliosis and
neurogenesis are active processes in this phenomenon.
Results
rNSCs and rMSCs before transplantation
Under the culture conditions chosen (Figs. 1Aa and Ba) and as
previously shown (Reynolds and Weiss, 1992; Wislet-Gendebien
et al., 2003, 2005), 99% of the rMSCs and rNSCs used for
transplantation were found to express the undifferentiated
precursor marker nestin, as well as GFAP (Figs. 1Ad and Bd).
The multipotential nature of rNSCs was demonstrated by their
ability to differentiate into neurons, astrocytes and oligodendro-
cytes following epidermal growth factor (EGF) starvation and
plating onto a coated surface (Figs. 1Be–g). As we have previously
shown, rMSCs were capable of differentiating into adipocytes,
chondrocytes and osteocytes (Wislet-Gendebien et al., 2003).
In order to identify the cells after transplantation, they were pre-
labeled with PKH26, a fluorescent lipophilic dye whose detection
does not require immunostaining. As shown in Figs. 1A (b–c) and
B (b–c), all cells displayed PKH26 staining in vitro. Notably,
PKH26 was localized at the perinuclear level in vitro (Fig. 1Ae). A
similar localization was also observed in vivo, 3 (Fig. 1Af) and 8
weeks (not shown) following transplantation, in sections counter-
stained with the nuclear dyes TOTO-3 iodide (Fig. 1Af) or Sytox
green (not shown). Importantly, the latter staining demonstrated
that, at 3 weeks post-transplantation and later, the presence of
PKH26 labeling in vivo was associated with intact and not
shrunken nuclei, indicating that the grafted cells did not undergo
massive cell death.
Striatal lesion, time of transplantation and sacrifice
In the protocol we used (Fig. 2A), rMSCs and rNSCs were
grafted 1 week following striatal injection of QA (QA/rNSCs and
QA/rMSCs groups). Control animals were injected with vehicle
alone (Vehicle/rNSCs and Vehicle/rMSCs groups). At this interval
after QA injection, we have previously demonstrated the presence
of striatal gliosis and inflammation characteristic of a pathologic
environment, but without ventricular enlargement or striatal atro-
phy (Bantubungi et al., 2005). 4 weeks following QA injection, we
observed significant ipsilateral striatal atrophy and enlargement of
the lateral ventricle (Fig. 2B). At this time point, we still observed
considerable gliosis, as characterized by a strong increase in the
number of CD11b-positive microglial cells and GFAP-immunor-
eactive cells, as well as a massive loss of NeuN staining within the
lesion core (see Fig. 9, Vehicle/DMEM vs. QA/DMEM animals).Very similar observations were made 9 weeks following lesion,
whether or not the animals were subsequently grafted with rNSCs
or rMSCs. These observations demonstrate the long-term persis-
tence of a pathological environment in this model and support the
view that the expression of CD11b and GFAP is related to the host
and not the grafted cells.Distribution of engrafted rMSCs and rNSCs
In order to estimate the impact of the degenerative environment
on the distribution of transplanted stem cells within the lesioned
striatum, we mapped cell distribution in a representative coronal
plane (rostro-caudal plane bregma +1 mm) in vehicle and QA-
lesioned rats. In addition, we used serial sections to determine the
rostro-caudal extent of the transplanted cells (see Experimental
methods). As shown in Fig. 3, we observed a profusion of grafted
cells within the lesioned area in QA-injected animals (Fig. 3A, upper
panels), whereas few cells remained in vehicle-injected animals
(Fig. 3A, lower panels) 3 weeks after transplantation, i.e., 4 weeks
Fig. 3. (A) Representative distribution of rNSCs grafted into a QA-lesioned animal (upper panel) or a vehicle animal (lower panel) 3 weeks post-transplantation
(i.e., 4 weeks post-lesion). For each panel, anatomical landmarks are represented using Hoechst counterstaining (left), cartography of cell distribution (middle)
and merge (right). Similar observations were made for short- and long-term groups regardless of the cell type. Note the relative paucity of grafted cells in sham-
lesioned animals compared to their abundance in the lesioned striatum. The lesion is indicated by an arrow. CC: corpus callosum, LV: lateral ventricle, ac: anterior
commissure, CX: cortex. (B) Occurrence of cells along the rostro-caudal axis of the striatum. Grafted cells can be readily seen throughout the length of the
striatum in the QA-lesioned animals whereas their distribution is limited to the vicinity of the needle track in vehicle-injected rats (short term: ST=3 weeks post-
transplantation; long term: LT=8 weeks post-transplantation). ⁎⁎⁎pb0.001 as compared to vehicle-treated rats; one-way ANOVA followed by LSD post hoc
test.
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days after transplantation into the sham-lesioned striatum (groups
Vehicle/rNSCs or rMSCs; not shown), supporting that the normal or
non-pathological environment did not favor the engraftment of cells.
The average number of grafted cells within the lesioned striatum 3
weeks post-transplantation was estimated to be 158,271±24,025
and 165,718±18,744 for rNSCs and rMSCs, respectively. This
provides further evidence for the long survival times of cells in thelesioned striatum, as well as their possible proliferation in vivo since
the number of cells originally grafted was around 100,000. The in
situ proliferation of grafted cells was also demonstrated by the
presence of numerous PKH26-positive cells displaying proliferating
cell nuclear antigen (PCNA) immunoreactivity within the lesioned
striatum (not shown). Finally, and in line, rMSCs and rNSCs were
more extensively distributed within the QA-lesioned striatum at both
short and long endpoints than unlesioned controls (Fig. 3B). Taken
458 K. Bantubungi et al. / Mol. Cell. Neurosci. 37 (2008) 454–470together, these data support the view that the lesioned environment
favors the proliferation and intralesional distribution of both types of
grafted stem cells. This effect was not transient or cell-specific since
similar observations were made regardless of cell type (rMSCs and
rNSCs) or post-transplantation time (3 weeks and 8 weeks; not
shown).
To establish that the PKH26 labeling observed within the
lesioned core corresponds to the presence of grafted cells and not
to membrane fragments of dead cells taken up by neighboring
resident cells such as microglia, we grafted stem cells that had been
stained and killed by repeated freeze–thaw cycles (Supplemental
data 1A) into QA-lesioned animals and compared their striatal
distribution with that of grafted PKH26-positive living cells
(Supplemental data 1B and C). Although the freeze–thaw cycles
did not alter the fluorescence properties of PKH26, only a few
fluorescent objects (probably auto-fluorescent red blood cells) were
detected at the level of the injection site (Supplemental data 1B,
lower panel) in animals grafted with killed cells and none
resembling the PKH26-labeled cells seen after grafts of living
cells (Supplemental data 1B, upper panel). At a more posterior
level (Supplemental data 1C), almost all PKH26-related fluores-
cence disappeared when cells were killed prior to transplantation,
further indicating that the PKH26 staining seen in our sections was
mostly due to the presence of grafted cells. These results support
the reliability of PKH26 dye “tagging” of migrating cells for the
present application, in agreement with previous studies (Lim et al.,
1997; Wichterle et al., 1999; Modo et al., 2002).Fig. 4. Increase in SCF expression in the QA rat model. SCF expression detected by
lesioned non-grafted rats 1 (B) and 4 (C–E) weeks post-injection. View at higher
incubation of the antibody with the immunization peptide abolishes staining both wi
in the lesion core presenting SCF immunoreactivity (green) 4 weeks post-lesion in
rNSCs groups) and that SCF expression was never observed in PKH26-positive cInvolvement of the stem cell factor
Our topological observations suggest the existence of a factor
produced by the lesioned striatum and capable of promoting the
survival, proliferation and migration of both stem cell types within
the lesion core following transplantation. SCF, the ligand for the
receptor c-kit, was a good potential candidate as previous
observations have indicated its pro-survival and chemoattractant
properties with regard to different types of stem cells, including
NSCs (Matsui et al., 1990; Erlandsson et al., 2004; Sun et al., 2004).
Using immunohistofluorescence, we found that, in sham-lesioned
animals (Vehicle/DMEM or Vehicle/grafts), SCF was expressed
almost exclusively in the ependymal layer of the subventricular zone
(SVZ; Fig. 4A), with a weak signal observed in the striatum (see
higher magnifications in Figs. 9–11). Conversely, a strong increase
in SCF expression was seen in the striatum ofQA-lesioned animals 1
week post-lesion (i.e., at the time of transplantation; Fig. 4B) as well
as at 3 (QA/DMEM animals; Figs. 4C and D) and 8 weeks (not
shown) post-transplantation (i.e., 4 and 9 weeks post-lesion), al-
though SVZ staining remained similar to controls (Figs. 4B–E). No
increase in SCF expression was observed in the intact contralateral
striatum (data not shown). The present observations thus demon-
strate a long-lasting upregulation of host SCF within the striatum of
QA-lesioned animals. The specificity of the SCF signal was
ascertained by pre-incubating the antibody with the immunization
peptide, which suppressed staining both within the SVZ and the
lesion (Fig. 4F). Importantly, enhanced SCF expression could beimmunohistofluorescence in the striatum of vehicle-injected rat (A) or QA-
magnification at the level of the lesion core (D) and the SVZ (E). (F) Pre-
thin the SVZ and the lesion. (G) Localization of PKH26-labeled rMSCs (red)
QA/rMSCs rats. Note that similar observations were made for rNSCs (QA/
ells. Scale bars: A–C and F=50 μm; D, E and G=20 μm.
Fig. 6. Activation of c-kit and c-kit-induced in vitro migration in cultured
rMSCs and rNSCs by recombinant SCF. (A) Effect of recombinant rat SCF
(100 ng/ml) on c-kit phosphorylation (P-c-kit) in rMSCs (left) and rNSCs
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shown). Furthermore, the localization of this sustained SCF
immunoreactivity was in perfect accordance with the distribution
of PKH26-positive cells in both long-term and short-term grafted
animals (QA/rMSCs or QA/rNSCs groups; Fig. 4G). It is worth
noting that the PKH26-positive grafted cells did not themselves
express SCF in lesioned animals (QA/rNSCs or QA/rMSCs groups;
Fig. 4G), and a similar pattern of SCF expression was observed in
lesioned animals that did not receive transplants (QA/DMEM
group). In contrast, striatal SCF expression was virtually absent in
sham-lesioned grafted animals (Vehicle/rNSCs and Vehicle/rMSCs
groups) as in the contralateral striatum of lesioned rats (see above).
These observations support the conclusion that the SCF expression
observed under lesion conditions (QA/rNSCs, QA/rMSCs and QA/
DMEM) was due uniquely to host cells.
We next decided to evaluate the potential functional activity of
the SCF expressed by host cells in the lesioned striatum towards
grafted stem cells. We examined the expression of the SCF
receptor c-kit by rMSCs and rNSCs, and its potential activation by
recombinant SCF or proteins extracted from the striata of 4-week
lesioned (non-grafted) rats, using biochemical and migration
assays. As shown by western blotting, both cell types, as well as
the SVZ dissected out from normal adult brains and used as a
positive control (Jin et al., 2002), expressed c-kit (Fig. 5A). This
expression was confirmed by pre-graft immunocytofluorescence in
rMSCs and rNSCs (Figs. 5B and C). To evaluate the functional
activation of c-kit in rMSCs and rNSCs, we exposed both cell
types to recombinant rat SCF (100 ng/ml). As shown in Figs. 6A
and B, SCF triggered the activation of c-kit in both cell types, as
demonstrated by an increase in the phospho-c-kit signal, and this
consequently resulted in the phosphorylation of Erk. The SCF-c-kit
pathway is well known as a promoter of migration in different
types of stem cells such as hematopoietic (Hassan and Zander,
1996 for review), spermatogonial (Ohta et al., 2003) and neural
stem cells (Jin et al., 2002; Erlandsson et al., 2004; Sun et al.,
2004). We therefore examined the possibility that the activation of
the c-kit pathway led to a similar functional effect, in addition to
the increased kinase activity detected biochemically. Using Boyden
chambers, we observed that 100 ng/ml SCF induced the in vitro
migration of both rMSCs and rNSCs by 24 h. This effect was
significantly decreased by pre-incubating the cells with a c-kit
blocking antibody (Fig. 6C).Fig. 5. Expression of c-kit as detected by western blotting (A) and
immunocytofluorescence in rMSCs (B) and rNSCs (C). Scale bar=10 μm.
(right). (B) Effect of recombinant rat SCF (100 ng/ml) on Erk phosphoryla-
tion (P-Erk) in rMSCs (left) and rNSCs (right). Quantification is indicated
below with controls set at 100%. ⁎pb0.05, ⁎⁎⁎pb0.001; one-way ANOVA
followed by multiple comparison Bonferroni post hoc test. (C) In vitro
migration of rMSCs (left) and rNSCs (right) following a 24-h stimulation
with 100 ng/ml of recombinant SCF in the presence or absence of c-kit
blocking antibody (Ab, 5 ng/ml). ⁎⁎⁎pb0.001; ##pb0.001; ###pb0.001;
one-way ANOVA followed by multiple comparison Bonferroni post hoc test
(groups being compared are indicated by horizontal bars).In order to assess whether the SCF produced locally within the
QA-lesioned striatum could similarly activate the c-kit signaling
pathway and promote their in vitro migration, protein extracts from
the injured (non-grafted) striatum were applied to both rMSCs and
rNSCs. This produced the phosphorylation of c-kit and Erk in these
cells, whereas protein extracts from control (vehicle-injected)
striata had no effect (Figs. 7A, B). In addition, the incubation of
cells with protein extracts from the QA-lesioned striatum
significantly increased the in vitro migration of rMSCs (Fig. 7C,
Fig. 7. Activation of c-kit and c-kit-induced in vitro migration in cultured
rMSCs and rNSCs by protein extracts from the striata of vehicle-lesioned
animals (V) or 4-week QA-lesioned animals (QA). (A) Effect of striatal
extracts on c-kit phosphorylation (P-c-kit) in rMSCs (left) and rNSCs (right).
(B) Effect of striatal extracts on Erk phosphorylation (P-Erk) in rMSCs (left)
and rNSCs (right). Quantification is indicated below with controls set at
100%. ⁎pb0.05; ⁎⁎⁎pb0.001. (C) In vitro migration of rMSCs (left) and
rNSCs (right) following a 24-h stimulation with protein extracts from the
striata of vehicle-lesioned animals (V) or 4-week QA-lesioned animals (QA)
in the presence or absence of c-kit blocking antibody (Ab, 5 ng/ml).
⁎⁎pb0.01; ⁎⁎⁎pb0.001; #pb0.05; ###pb0.001; one-way ANOVA fol-
lowed by multiple comparison Bonferroni post hoc test (groups being
compared are indicated by horizontal bars).
Fig. 8. Proliferation of rNSCs (A) and rMSCs (B) following a 5 day
stimulation with 10 ng/ml of recombinant SCF, as measured using an assay
for MTS reduction (indicator of cell number). ⁎pb0.05; ⁎⁎⁎pb0.001; one-
way ANOVA followed by LSD post hoc test.
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when compared to an incubation with extract from non-lesioned
striatum. Importantly, the c-kit blocking antibody reversed themigration promoted by QA extracts to near baseline levels (115.8
and 100.8% of the value for rMSCs and rNSCs treated with vehicle-
extract, respectively). The latter observation thus supports a role for
locally produced SCF following QA lesioning in the migration of
mesenchymal and neural stem cells within the striatum.
In addition to their intralesional migration, grafted cells may
also proliferate, as suggested by our cell count and PCNA staining
(see above). Given that SCF has been suggested to induce the
proliferation of various cell types (McNiece and Briddell, 1995), it
was thus possible that SCF influences the in situ proliferation of
grafted cells. To test this possibility in vitro, we applied a low dose
of recombinant SCF daily to our cells and measured their pro-
liferation after 5 days. We found a small but statistically significant
increase in the proliferation of rMSCs and rNSCs in the presence
of the factor (Figs. 8A, B). Taken together, our data lead us to
believe that the local production of SCF by host cells following
striatal lesion promotes the proliferation of grafted neural stem
cells, in addition to their migration.
Finally, we have estimated the role of endogenous SCF
produced within the lesion core by grafting, in lesioned animals,
rNSCs pre-treated for 6 h with a c-kit blocking antibody. As shown
in Fig. 9, treatment with the c-kit blocking antibody modified the
distribution of grafted cells along the antero-posterior axis. The
number of rNSCs present at levels anterior to the injection site was
decreased when cells were treated by the c-kit blocking antibody
and there was no cell accumulation at the level of the graft core.
These data suggest that c-kit receptor blockade might influence the
survival and/or the proliferation of neural stem cells in vivo.
Nature of SCF-expressing cells
In order to determine the phenotype of SCF-positive cells in
the host brain following striatal lesion, we performed double
immunostaining using anti-NeuN, anti-CD11b and anti-GFAP
Fig. 9. Distribution of rNSCs within the lesion core of rats grafted with cells
pre-treated or not with the c-kit blocking antibody (Ab). ⁎pb0.05 vs.
untreated cells.
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observed that SCF was neither localized in the NeuN-positive
neurons remaining at the lesion site nor in the activated CD11b-
positive microglial cells (Figs. 10B and D). Conversely, numerous
GFAP-positive cells exhibiting large cell bodies and thick pro-
cesses displayed SCF expression within the lesioned area, and
almost all the SCF-positive cells were also positive for GFAP
(Fig. 10F). This colocalization was not limited to the lesioned area
since we also observed GFAP+/SCF+ cells within the dorso-lateral
part of the subventricular zone (SVZ; Supplemental data 2). No-
tably, GFAP+/SCF+ staining could also be observed, although to a
lesser extent, in the dorso-lateral SVZ of vehicle-treated unlesioned
rats. Similar observations were made when SCF/S100β double stain-
ingwas performed (not shown). These data support the possibility that
SCF is expressed by a sub-population of host astroglial cells following
striatal lesion.
When we checked the topology of SCF staining, we observed
that the density of host cells expressing SCF within the dorsal
subventricular zone (dSVZ) at anterior striatal levels was strongly
increased in animals in the short- (Fig. 11B) and long-term
lesioned groups (not shown) when compared with controls
(Fig. 11A). Doublecortin (DCX) immunostaining revealed that
the increased SCF staining within the dSVZ was accompanied by
an increase in thickness as well as a change in the axis of the
latter (Fig. 11B; see arrows and Supplemental data 3), suggesting
an increase in the production of neural progenitors in order to reach
the lesion. In accordance with this view, within the dSVZ
(Fig. 11B) as well as in the intermediate zone extending from
the dSVZ to the lesion (Fig. 11C; see Supplemental data 3 for a
low magnification view), many DCX-labeled cells displayed the
morphological features of migrating neuroblasts, with elongated
leading processes. These changes were not observed in 1-week
lesioned animals (not shown), supporting the occurrence of a
progressive increase in neurogenesis and progenitor migration in
the QA model. In both the areas mentioned above, many DCX-
positive cells co-expressed SCF in 4-week QA-lesioned animals,
whereas few double-labeled cells were observed in controls,
suggesting that a fraction of the SCF-expressing cells might be
progenitors migrating from the dSVZ. Increased DCX immunor-
eactivity was also found within the lesion site (Fig. 11E).
Interestingly, a substantial number of striatal DCX-positive cellswere labeled with the anti-SCF antibody (Fig. 11E). Given our
previous GFAP and S100β immunolabeling results, these observa-
tions suggest that cells that express SCF could be simultaneously
positive for DCX, GFAP and S100β. This view was supported by
other double and triple immunolabeling studies. In the lesion core,
DCX-positive cells presented the large cell bodies and thick
processes seen with SCF+/GFAP+ cells (see Figs. 10F and 11E).
Using GFAP/DCX double labeling, we observed that, in the lesion,
such DCX-positive cells strongly co-expressed GFAP (Fig. 12B)
whereas these markers were not colocalized either within the dSVZ
(Supplemental data 4) or the rest of SVZ (not shown). Similar
observations were made following double DCX/S100β staining
(Supplemental data 5). Substantial co-expression of SCF, GFAP
and DCX within the same cells was confirmed by triple labeling
(Fig. 12C). Finally, we found that DCX-positive cells also co-
expressed nestin (Fig. 12E), suggesting that SCF-expressing cells
within the lesion may represent a mix of atypical reactive
astrocytes and neuronal progenitors. Accordingly, the majority of
GFAP-positive cells exhibiting thick processes were stained for
nestin (not shown).
Discussion
Endogenous neural progenitors have the ability to proliferate
and/or migrate towards brain lesions in various pathological
models as well as in the diseased human brain (Arvidsson et al.,
2002; Curtis et al., 2003; Sun et al., 2004; Tattersfield et al., 2004).
Exogenous stem cells also display an ability to migrate and survive
in the lesioned parenchyma following transplantation (Eglitis et al.,
1999; Mahmood et al., 2001; Imitola et al., 2004; Hill et al., 2004).
However, little is known about the factors controlling these events
and the potential of endogenous progenitors to favor the
engraftment, migration and proliferation of exogenous progenitors.
Our results show that rMSCs and rNSCs display a similar
distribution once grafted within the sham-lesioned or lesioned
brain. In a normal environment, even though cells could be
detected in the striatum at very short time intervals after grafting,
few were present in this region 3 or 8 weeks after transplantation.
Conversely, when cells were grafted following an excitotoxic
insult, they were massively present and distributed throughout the
lesioned structure. Our observations are also in accordance with the
general view that the environment of the diseased brain promotes
the survival and migration of grafted stem cells (see Bjorklund and
Stenevi, 1984; Sotelo and Alvarado-Mallart, 1987 but also Watts
and Dunnett, 1998; Eglitis et al., 1999; Nishino et al., 2000;
Mahmood et al., 2001; Imitola et al., 2004; Hill et al., 2004; Kelly
et al., 2004; Geloso et al., 2007) and lead us to suggest that at least
one factor present within the lesion core promotes the engraftment
of these two types of exogenous stem cells of distinct embryonic
origins. One such factor could be SCF, shown to be mitogen and
chemoattractant for many cells in the hematopoietic system, with
the ability to enhance the mobilization of peripheral blood
progenitor cells (McNiece and Briddell, 1995; Glaspy, 1996) and
to stimulate neurogenesis as well as the migration of endogenous
neural stem cells in vivo (Jin et al., 2002; Sun et al., 2004). Indeed,
from 1 to 9 weeks post-lesion, we found a strong increase in SCF
expression, restricted to the site of stem cell engraftment within the
striatum. SCF is known to activate its receptor, c-kit, stimulating
receptor autophosphorylation and downstream signaling pathways
that involve phosphatidylinositol-3-kinase, Src, JAK/STAT and/or
MAP kinases (Linnekin, 1999; Wandzioch et al., 2004). c-kit is
Fig. 10. Absence of SCF in mature neurons and microglial cells in the lesion core. SCF (green) does not colocalize with NeuN (red in A, B) or CD11b (red in C, D) in
Vehicle/DMEM animals (A, C) or in 4-week QA-lesioned animals (QA/DMEM group; B, D). SCF (green) did colocalize with GFAP (red) in lesion core of QA-injected
animals (F). No colocalization is seen in the control striatum (E). TOTO-3 iodide nuclear counterstaining is shown in blue. Scale bar=20μm. Staining patterns were similar
regardless of whether the animals received rMSCs or rNSCs (Vehicle/rMSCs or rNSCs and QA/rMSCs or rNSCs), demonstrating that the staining seen following QA
lesions is of host origin.
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Fig. 11. SCF is expressed by neural progenitors following QA lesion. Colocalization of SCF (green) with DCX (red) in coronal sections from Vehicle/DMEM
animals (A, D) and 4-week QA-lesioned animals (QA/DMEM group; B, C, E). Following QA lesion, expression of SCF and DCX is increased within the dorso-
lateral part of the SVZ where many cells express both markers (B; control animal shown in A; inset in A indicates where photomicrographs were taken). Arrows
represent the general axis of the dorso-lateral part of the SVZ. Colocalization also occurs in the area between the rostral migratory stream and the lesion core (C).
(E) Most SCF-expressing cells in the striatal lesion coexpress DCX. (D) Striatum of a control rat. Results were similar for 8-week QA-lesioned animals. TOTO-3
iodide nuclear counterstaining is shown in blue. Scale bar=20 μm. Staining patterns were similar regardless of whether the animals received rMSCs or rNSCs
(Vehicle/rMSCs or rNSCs and QA/rMSCs or rNSCs) demonstrating that the staining observed following QA lesions is of host origin.
463K. Bantubungi et al. / Mol. Cell. Neurosci. 37 (2008) 454–470expressed not only by rNSCs as previously suggested (Sun et al.,
2004) but also by the nestin-positive rMSCs used in our study. In
line with this observation, we demonstrated that the c-kit signalingpathway could be activated by recombinant SCF within these cells.
Moreover, protein extracts from QA-lesioned striata were also able
to activate the c-kit signaling pathway within rMSCs and rNSCs,
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and can stimulate the grafted cells. In addition, we found that both
recombinant SCF and striatal extracts from lesioned animals
promote the migration of rMSCs and rNSCs in vitro. TheseFig. 12. Presence of atypical DCX/GFAP/SCF-expressing cells within the lesion co
(A) and 4-week QA-lesioned animals (QA/DMEM group; B). (C) Triple SCF (gre
lesioned animals (QA/DMEM). Costaining of Nestin (green) and DCX (red) in Ve
TOTO-3 iodide nuclear counterstaining is shown in blue in A, B, D and E. Scale
whereas in D and E, a polyclonal one was used. Staining patterns were similar rega
rNSCs and QA/rMSCs or rNSCs) demonstrating that the staining observed followobservations agree with recent studies reporting that Erk activation
is associated with the homing of NSCs promoted by SDF-1α within
the ischemic brain (Imitola et al., 2004) and the pro-survival and pro-
migratory effect of SCF towards NSCs (Jin et al., 2002; Erlandssonre. Colabeling of DCX (green) with GFAP (red) in Vehicle/DMEM animals
en)/DCX (red)/GFAP (blue) labeling within the lesion core of 4-week QA-
hicle/DMEM animals (D) and 4-weeks QA-lesioned animals (QA/DMEM).
bar=20 μm. Note that in A and B, a monoclonal GFAP antibody was used
rdless of whether the animals received rMSCs or rNSCs (Vehicle/rMSCs or
ing QA lesions is of host origin.
465K. Bantubungi et al. / Mol. Cell. Neurosci. 37 (2008) 454–470et al., 2004; Sun et al., 2004). Also, as previously shown for other
cell types (McNiece and Briddell, 1995), we obtained in vivo (our
cell counts and PCNA staining) and in vitro (MTT assay) data
showing that SCF significantly increased the proliferation of stem
cells. Finally, in line with recent in vitro observations (Erlandsson et
al., 2004), we obtained in vivo data suggesting that the blockade of c-
kit receptor prior transplantation alters the proliferation/survival of
rNSCs. Taken together, our results indicate that SCF produced
within the lesioned striatum may contribute to the migration,
survival and proliferation of stem cells following transplantation.
Besides SCF, other factors could be involved. Indeed, the injection
of TGFα into the dopamine-denervated striatum promote the
migration of adult neural progenitors from the subventricular zone
(Cooper and Isacson, 2004); the ciliary neurotrophic factor (CNTF)
promotes the differentiation and thus the survival of exogenous stem
cells in the QA-lesioned environment (McBride et al., 2004); the
chemokine SDF-1α, which is upregulated following QA injection
(Croitoru-Lamoury et al., 2003) as well as other chemokines
(Belmadani et al., 2006), has been shown to direct the migration of
neural stem cells and to promote the homing of bone marrow stem
cells following hypoxia/ischemia (Imitola et al., 2004; Hill et al.,
2004).
The increased SCF expression detected in our QA-lesioned rats
was not due to neuronal or microglial production since we did not
observe co-labeling with NeuN or CD11b. This negative observation
does not however rule out the possibility that the important microglial
reaction present in the lesioned striatum influences the expression of
SCF by surrounding cells. Strikingly, we found that most SCF-
positive cells also expressed DCX. This is true for the dSVZ and
extends up to the lesion core, where strong DCX upregulation can be
seen. The expression of DCX, a marker for migrating neuronal
progenitors, is an indication of neurogenesis as in the adult brain,
within areas of continuous neurogenesis (Brown et al., 2003), or in
case of increase in brain neurogenesis induced by environmental
factors or insults (Couillard-Despres et al., 2005). Such an increase in
neurogenesis following QA injection is in line with previous findings
(Tattersfield et al., 2004; Collin et al., 2005). Our data thus support the
view that SCF is produced, at least in part, by neural progenitors that
migrate from the dorsal subventricular zone.
Increased neurogenesis is a common feature of various neurolo-
gical conditions such as stroke, Alzheimer's disease and Hunting-
ton's disease (Curtis et al., 2003; Kokaia and Lindvall, 2003; Jin
et al., 2004). However, its exact functional consequence remains
unclear (Emsley et al., 2005) as the recruitment of endogenous
neural stem cells is clearly insufficient to compensate for the
progressive cell loss that occurs. SCF-expressing cells were strongly
co-labeled with GFAP and S100β, suggesting that this factor may
also be released by atypical DCX-expressing astroglial cells present
in the lesion core. It is also worth mentioning that neural progenitor
cells co-expressing the neuronal and glial markers, GFAP, nestin and
βIII-tubulin have been recently characterized in the human fetal
brain (Rieske et al., 2007). Ultimately, pathology-induced events
such as neurogenesis and gliosis may promote the in situ delivery of
factors important for stem cell engraftment and migration and are
thus crucial for cell-based therapeutics. In this way, the local delivery
of factors such as SCF, possibly by the grafted stem cells themselves,
may increase their clinical potency. Furthermore, as supported by
recent data, SCF delivery may also provide additional protective
effects against excitotoxic neuronal death (Dhandapani et al., 2005)
that plays a major role in various neurological conditions (Greene
and Greenamyre, 1996).Experimental methods
Mesenchymal stem cell cultures
Rat mesenchymal stem cells (rMSCs) were obtained from 12-week-old
adult Wistar rat bone marrow as we have previously described (Wislet-
Gendebien et al., 2003, 2005; Fig. 1Aa). Between 100 and 200×106
marrow cells were plated in T75 tissue culture flasks in DMEM/10% fetal
bovine serum (Invitrogen, Belgium). After 24 h, non-adherent cells were
removed by renewing the medium. When the rMSCs reached confluence,
they were resuspended in 0.25% trypsin and 1 mM EDTA and sub-cultured.
To initiate nestin expression, 10 passages (which correspond to 25 popu-
lation doublings) of rMSCs were grown in DMEM/F12 medium (Wislet-
Gendebien et al., 2003). Cells were then prepared for transplantation,
activity and migration tests or mounted on poly-ornithine-coated coverslips
for immunocytofluorescence as described below.
Neural stem cell cultures
Rat neural stem cells (rNSCs) were obtained from the lateral (LGE) and
medial ganglionic eminences (MGE) of 17- to 18-day-oldWistar rat embryos
and prepared as described (Reynolds and Weiss, 1992; Fig. 1Ba). For
dissociation, plating and maintenance, we used DMEM/F12 (1:1, v/v)
complemented by B27 and N2 (Invitrogen, Belgium) in the presence of
20 ng/ml of epidermal growth factor (EGF; Sigma, Belgium). Briefly, the
brain and meninges were removed. The LGE and MGE were carefully
dissected out and mechanically dissociated in the culture medium by
trituration with a polished Pasteur pipette. Once dissociated and counted
using Trypan blue, viable cells were seeded at 2×105 cells/ml in uncoated
T75 tissue culture flasks. Cells proliferated and formed spheres in
suspension. Half the serum-free medium was renewed after 2 days. Ten
days after plating, primary neurospheres were mechanically dissociated into
single cells. Three days after the passage, cells were prepared for
transplantation, activity and migration tests or mounted on poly-ornithine-
coated coverslips for immunocytofluorescence as described below.
Preparation of cells before transplantation
rMSCs (passage 10 or more) and rNSCs (at passage 2) were labeled
with PKH26, 72 h before transplantation. PKH26, a non-toxic fluorescent
lipophilic dye (Ashley et al., 1993), was added to the cultures at a con-
centration of 4 μM according to the manufacturer's instructions (Sigma,
Belgium). This protocol resulted in the labeling of all cells in vitro
(Figs. 1Ac and Bc).
Pre-graft immunocytofluorescence
To characterize the phenotype of rMSCs and rNSCs prior to
transplantation, a subset of cells mounted on poly-ornithine-coated
coverslips were fixed with 4% paraformaldehyde for 20 min at room
temperature and washed 3 times in 0.01 M PBS. Non-specific binding was
blocked by a 1-hour incubation in 0.01 M PBS containing 10% normal
horse serum and 0.1% Triton. The cells were incubated overnight at 4 °C
with rabbit polyclonal anti-GFAP (1/1000, G9269, Sigma, Belgium), mouse
monoclonal anti-nestin (1/1000, rat401, Pharmingen, USA), rabbit poly-
clonal anti-MAP2 (1/1000, a gift from JP Brion, Brussels, Belgium), mouse
monoclonal anti-CNPase (1/1000; C5922, Sigma, Belgium) or goat polyclonal
anti-c-kit (1/1000, sc-1494, Santa-Cruz, USA) primary antibodies (diluted in
0.01 M PBS). After three washes, the cells were incubated in biotinylated
donkey anti-mouse IgG, anti-rabbit IgG or anti-goat IgG (1/200, Jackson
ImmunoResearch, USA) for 1 h at room temperature. After washing, the cells
were incubated in FITC or Cy-3 conjugated with streptavidin (1/200, Vector
Laboratories, USA) for 1 h at room temperature. All preparations were
mounted with a SlowFade Light anti-fade kit (Molecular Probe, USA) and
observed using a laser-scanning confocal microscope (see below).
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QA lesions and transplantations were performed on adult male Wistar
rats (225–250 g, Charles River, Belgium). Animals were housed four per
cage with food and water ad libitum and maintained in a temperature- and
humidity-controlled room with a 12 h light/dark cycle. The number of
animals used was kept to a minimum and all efforts to avoid animal
suffering were made in accordance with the standards of the Institutional
Ethical Committee.
An initial experiment (Exp. I) was realized to monitor stem cell
distribution within the normal and QA-lesioned striatum at short (3 weeks)
or long (8 weeks) time periods following transplantation (see Fig. 2A). To
this end, rats were randomly divided into six experimental groups: control
rats (injection of vehicle/injection of DMEM; n=10), vehicle/rNSC-grafted
animals (n=16), vehicle/rMSC-grafted animals (n=16), quinolinic acid
(QA)-lesioned animals/injection of DMEM (n=16), QA-lesioned/rNSC-
grafted animals (n=16) and QA-lesioned/rMSC-grafted animals (n=16).
For each injection (vehicle, QA, DMEM or cells), rats were anesthetized
with a xylazine/ketamine mixture (Rompun, Bayer; 4.5 mg/kg; Imalgene,
Merial; 90 mg/kg) and placed in a Kopf stereotaxic frame with the incisor
bar set at −2.3 mm below the interaural line. QA was prepared in 0.01 M
PBS (pH 7.4) as previously described (Bensadoun et al., 2001; Bantubungi
et al., 2005). Each rat was injected with either 1 μl of QA (180 nmol;
Sigma, Belgium) or 1 μl of PBS (vehicle) in the right striatum at the
following stereotaxic coordinates: AP: +1.0 mm, ML: −3.5 mm, DV:
−5.0 mm. The injection was performed using a 28-gauge 10 μl Hamilton
syringe over a period of 4 min. One week after the QA lesion, all rats were
anesthetized again, placed in the stereotaxic apparatus and received
unilateral cellular transplants (or only DMEM) in the previously QA-
lesioned or intact contralateral striatum at two sites: AP: +1.0 mm, ML:
−3.0 mm, DV: −4.5 mm and −5.0 mm. At both sites, cells were injected in
two 2 μl deposits over 16 min using a 25-gauge 10 μl Hamilton syringe.
Each animal received 50,000 cells at each of the two injection sites
(100,000 cells in total). Half the animals in each group was sacrificed at
3 weeks post-transplantation (i.e., 4 weeks post-lesion) and the other half at
8 weeks post-transplantation (i.e., 9 weeks post-lesion).
In a second experiment (Exp. II), another 22 rats were injected with
vehicle (n=11) or QA (n=11) following the protocol indicated above. Half
of each group was sacrificed at 1 week post-lesion for immunohistochem-
istry and the remaining animals were sacrificed 4 weeks post-lesion for
biochemical tests.
We performed control experiments (Exp. III) to ensure the reliability of
PKH26 labeling for the monitoring of cell migration in the present
experiments. We grafted pre-stained rMSC cells, live or killed before
transplantation (n=3 per group). Cells were killed by four successive
freeze–thaw cycles (liquid nitrogen was used to freeze the cells, a 37 °C
water bath was used for thawing; personal communication from Alvarez-
Buylla and Lim). Cells were grafted as described above and the animals killed
3 weeks post-transplantation. At the time of transplantation, a similar number
of cells from each group was replated and observed after 5 days to ensure that
freeze–thawed cells had been completely killed (see Supplemental data 1).
Ten additional rats (Exp. IV) were used to monitor the effect of the
blocking c-kit antibody on the striatal distribution of neural stem cells within
the lesioned striatum. QA injections were performed as indicated above. One
week after QA injections, all rats were anesthetized again, placed in the
stereotaxic apparatus and received rNSCs (n=10) unilateral cellular implants
into the previously QA-lesioned striatum at two sites: AP: +1.0 mm, ML:
−3.0 mm, DV: −4.5 mm and −5.0 mm. At both sites, cells were injected in
two 2 μl deposits over 16 min using a 25-gauge 10 μl Hamilton syringe. Each
animal received approximately 50,000 cells at each of the two injection sites.
In half the animals, PKH26-labeled neural stem cells were treated 6 h prior
transplantation with the rat anti-mouse blocking c-kit antibody (50 ng/ml in
DMEM; CD117 c-kit monoclonal antibody clone ACK45, Pharmingen,
Belgium), resuspended in DMEM containing the same concentration of
blocking antibody and grafted following the protocol indicated above. All the
animals were sacrificed 3 weeks post-lesion for histological evaluation and
cell counts.Brain processing
After completion of the treatment protocols, animals were injected with
an overdose of a xylazine/ketamine mixture and transcardially perfused
with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Brains were
removed and post-fixed for 16 h in the same fixative, washed with 0.01 M
PBS and transferred successively for 24 h each into 10%, 20% and 30%
sucrose solutions in 0.1 M phosphate buffer. Brains were finally embedded
in Tissue Tek and frozen using −40 °C isopentane. For experiments I and II,
serial 16-μm-thick coronal sections were made using a cryostat at the level
of the striatum, and mounted onto poly-L-lysine-coated slides. More
precisely, we took all the 16-μm-thick sections from the planes ~+2.5 to
−1.5 mm from the bregma. We placed three consecutive sections on the
same slide and obtained ~80 slides per animal, allowing a complete
analysis of the region along the antero-posterior axis. For experiment III,
20-μm-thick serial coronal cryostat sections were obtained and mounted
onto poly-L-lysine-coated slides. More precisely, we took all the 20-μm-
thick sections from the planes ~+2.5 to −1.5 mm from the bregma. We
placed four consecutive sections on the same slide and obtained ~50 slides
per animal.
The protein extracts used in biochemical assays were obtained as follows.
The striata of 4-week lesioned rats or vehicle-treated animalswere dissected out
from 1-mm-thick sections. Care was taken to exclude the SVZ from this
preparation. The tissue was then homogenized inM-PER buffer (Pierce, USA)
containing protease inhibitors (Complete, Roche Molecular Biochemicals,
Germany). Salts were removed from the homogenates and the proteins
concentrated usingMicrocon column (YM-3,Millipore, USA). Finally, protein
levels were quantified using the MicroBCA assay (Pierce, USA).
Immunohistochemistry
Immunohistochemical detection of SCF was performed as follows:
sections were incubated in 10% normal goat serum in PBS containing 0.1%
Triton for 1 h, and then incubated overnight at 4 °C with rabbit polyclonal
anti-SCF (1/250, 1498P, Chemicon, USA). The following day, sections
were rinsed, incubated for 1 h with HRP goat anti-rabbit secondary
antibody (1/100, TSA kit, NEN Life Science Products, Belgium), washed
three times in 0.01 M PBS and incubated in biotinylated tyramide (TSA kit,
NEN Life Science Products, Belgium) for 5 min at room temperature. The
specificity of the SCF staining was assessed by pre-incubating the primary
antibody with a 10-fold excess of recombinant mouse SCF immunization
peptide (PeproTech, UK). For double labeling, sections were then incubated
in 10% normal horse serum in 0.01 M PBS containing 0.1% Triton for 1 h
and incubated overnight at 4 °C with either guinea-pig polyclonal anti-DCX
(1/100, AB5910, Chemicon, USA), mouse monoclonal anti-GFAP (1/100,
G3893, Sigma, Belgium), mouse monoclonal anti-S100β (1/500; SB6,
Abcam), rabbit polyclonal anti-S100β (1/500; Dako), mouse monoclonal
anti-NeuN (1/100, MAB377, Chemicon, USA) or mouse monoclonal anti-
CD11b primary antibodies (1/100; MCA275; Serotec, Belgium). The next
day, sections were rinsed in 0.01 M PBS and incubated for 1 h in
biotinylated donkey anti-mouse IgG or anti-rabbit IgG (1/200, Jackson
ImmunoResearch, USA) or anti-guinea-pig IgG (1/200, Vector Labora-
tories, USA) for 1 h at room temperature. Finally, sections were incubated
in FITC conjugated with streptavidin (1/200, Vector Laboratories, USA) for
1 h at room temperature.
For double DCX/GFAP labeling, sections were incubated in 10% normal
horse serum in PBS containing 0.1% Triton for 1 h and then overnight at 4 °C
with guinea pig polyclonal anti-DCX (1/5000, AB5910, Chemicon, USA),
and the next day with mouse monoclonal anti-GFAP (1/100, G3893, Sigma,
Belgium). The TSA-signal amplification system (NEN-Life Science,
Belgium) and Cy3-conjugated IgG system were employed as described
above.
For double Nestin/GFAP and Nestin/DCX labeling, immunohistochem-
istrywas performed as follows: the sectionswere incubated in 10%normal goat
serum in PBS containing 0.1% Triton for 1 h and then overnight at 4 °C with
mouse monoclonal anti-nestin (1/100, rat403, Pharmingen, Belgium), and the
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guinea-pig polyclonal anti-DCX (1/100, AB5910, Chemicon, USA). The
TSA-signal amplification system (NEN-Life Science, Belgium) and Cy3-
conjugated IgG system were employed as described above.
Triple labeling for SCF/DCX/GFAP was performed as follows: the
sections were incubated in 10% normal goat serum in PBS containing 0.1%
Triton for 1 h and then overnight at 4 °C with rabbit polyclonal anti-SCF
(1/250, 1498P, Chemicon, USA). The next day, the SCF signal was
revealed using the TSA-signal amplification system (NEN-Life Science,
Belgium). We then incubated the sections with guinea-pig polyclonal anti-
DCX (1/100, AB5910, Chemicon, USA) and mouse monoclonal anti-
GFAP (1/100, G3893, Sigma, Belgium) overnight at 4 °C. Detection was
realized using, respectively, Cy3- and Cy5-conjugated IgGs.
For the PCNA labeling, sections were incubated in citrate buffer (300ml)
and heated with a microwave (4 min at 800Wand 2×5 min at 400W). Next,
the sections were incubated in 10% normal horse serum in PBS containing
0.1% Triton-X100 for 1 h and then overnight at 4 °C with mouse monoclonal
anti-PCNA (1/500, sc-56, Santa Cruz, USA). The signal was revealed using
the TSA-signal amplification system (NEN-Life Science, Belgium) as
described above (Chemicon, USA).
In all cases except the triple labeling, sections were counterstained with
the nuclear dyes Hoechst or TOTO-3 iodide (Molecular Probes, USA) and
then mounted with FluorSave reagent (Calbiochem, France).
Hoechst and TOTO-3 iodide counterstaining
For Hoechst (Molecular Probes, USA) nuclear counterstaining, sections
were incubated for 5 min in 160 μM Hoechst in 0.01 M PBS. Sections were
then rinsed in 0.01 M PBS. For TOTO-3 iodide (Molecular Probes, USA)
nuclear counterstaining, sections were incubated for 2 h in 1 μM TOTO-3
iodide in 0.01 M PBS and rinsed as above. All sections were mounted with
FluorSave reagent (Calbiochem, France).
Cytochrome oxidase staining
Frozen sections mounted on poly-L-lysine-coated slides were incubated
for 3×10 min in phosphate buffer (0.1 M, pH 7.4). Thereafter, slides were
incubated overnight in the dark in phosphate buffer (0.1 M, pH 7.4)
containing 4% sucrose, 0.05% Diaminobenzidine (DAB, Sigma, Belgium)
and 0.02% cytochrome c (Sigma, Belgium). Finally, slides were rinsed in
phosphate buffer (0.1 M, pH 7.4) and mounted with DPX. QA-induced
lesions appeared as a blank area in these sections (Fig. 2B).Laser-scanning confocal microscopy (LSCM)
The immunofluorescent sections or pre-grafted cells were analyzed with
a laser-scanning confocal microscope (LSM 510 Meta Confocal, Zeiss,
Germany).Rostro-caudal distribution of grafted cells
The distance of migration of the transplanted cells from the injection
site was defined rostro-caudally as the length between the first section
where PKH26-positive cells were present in the striatum and the first
section where no more PKH26-positive cells could be seen in the striatum.
This was achieved by the observation of all frozen, unmounted sections
from each rat under the fluorescent microscope. This allowed us to keep the
section available for further histological processing such as cytochrome
oxidase staining, counting and immunohistochemistry.
Cell counts
The number of PKH26-labeled rMSCs and rNSCs in the striatum was
counted in coronal sections using a semi-automated method (Bizat et al.,2003, Arango et al., 2006). Coronal sections 400 μm apart containing the
striatum were scanned with a 20× objective, using a Zeiss Axioplan2
imaging microscope motorized for X, Y and Z displacements. For each
section, an area encompassing the entire region displaying PKH26
fluorescence (from 0.48 to 5.1 mm2) was acquired using the acquisition
system (Morphostar 5.12, IMSTAR, Paris). This corresponds to 8 to 81
digitized images of contiguous 278.8 μm×227.6 μm fields of view (i.e.,
0.063 mm2). Image pixels were 0.40 μm×0.40 μm. Section fluorescence
(excitation) was similar for all acquisitions and homogeneity was
automatically corrected using blank images. Images were automatically
segmented for the quantification and (X,Y) localization of fluorescent objects
(PHK26-containing cells), using the same parameters defining fluorescence
intensity threshold and object size filters. Since fluorescence intensity was
slightly variable from one section to another, we normalized the analysis by
defining the light intensity threshold at 3 standard deviations above the
average light intensity detected over the entire section. With this procedure,
PHK26-labeled objects with an apparent cross-sectional area greater than
2 μm2 were reliably detected. For all images, objects touching one of the X or
Y borders of the fields of view were eliminated. We counted from 30 to 5404
objects/region displaying PHK26 fluorescence (depending on the section in
question) and the apparent cross-sectional area was recorded in each case.
The estimated total number of PHK26 objects (Ne) was corrected for bias
resulting from section thickness (20 μm) using the Abercrombie factor
(Clarke, 1992). This was possible since most PHK26 labeling was round
(mean rotundity index ~1) with an isotropic orientation in the striatum. This
factor (A) was estimated to be 0.8196, based on the mean object height
determined from observation of the objects detected in each experimental
group. The corrected number of PHK26 positive objects (Nc) per section was
calculated as Nc=A×Ne. The total number of stained cells per striatum was
calculated by first estimating the volume of the striatum from the number of
sections obtained per hemisphere (see previous paragraph), and then
multiplying by Nc.In vitro c-kit activity test
To test c-kit activity, rMSCs and rNSCs were starved of fetal bovine
serum (rMSCs) or B27/N2/EGF (rNSCs) for 4 h and stimulated for 20 min
with 100 ng/ml of recombinant rat SCF (PeproTech, UK) or with purified
protein extracts from 4-week QA-lesioned or vehicle rats (30 μg in 1 ml of
culture medium). The cells were harvested and washed in cold 0.01 M PBS
and proteinswere extracted at 4 °C for 1 hwith shaking, using a solubilization
buffer containing 80 mM Tris–HCl, 150 mM NaCl, 20 mM EDTA pH 7.5,
200 mM NaF, 1% Brij, 4 mM vanadate, 5 mM Na2PO4. 10 H2O, 10 μM
okadaic acid and protease inhibitors (Complete, Roche Molecular Biochem-
icals, Germany). Extracts were cleared by centrifugation at 13,000 rpm for
30 min at 4 °C. The protein extracts were then removed and stored at −20 °C
until analysis. Protein concentrations were quantified using MicroBCA
Protein Assay (Pierce, USA).Western blotting
Western blotting experiments were performed as we have previously
described (Blum et al., 2002). Equal amounts of protein (40 μg) were
denatured in Laemmli buffer at 100 °C, loaded onto 6% SDS–
polyacrylamide gels (for phospho-c-kit and c-kit detection) or 12% SDS–
polyacrylamide gels (for phospho-p44/42 MAPK and p44/42 MAPK
detection) and transferred onto nitrocellulose at a constant current of 25 V
for 1 h (Trans-blot, semi-dry transfer cell, Biorad, Belgium). The primary
antibodies used were goat anti-c-kit (1/500, sc-1494, Santa Cruz, USA),
rabbit anti-phospho-c-kit (1/500, 3391, Cell Signaling, USA), rabbit anti-
p44/42 MAPK (1/2000, 9102, Cell Signaling, USA) and mouse anti-
phospho-p44/42 MAPK (1/500, 9101, Cell Signaling, USA). Following
overnight incubation at 4 °C, membranes were washed and incubated with
biotin-labeled secondary antibodies, i.e., donkey anti-rabbit IgG (1/2000),
anti-mouse IgG (1/1000) or anti-goat IgGs (1/10000), and then with avidin–
biotin–peroxidase complex (Vectastain ABC kit, Vector Laboratories).
468 K. Bantubungi et al. / Mol. Cell. Neurosci. 37 (2008) 454–470Signals were detected using the chemiluminescent ECL reagent (Perki-
nElmer, Life Technologies).
In vitro migration assay
Briefly, recombinant rat SCF (100 ng/ml; PeproTech, UK) diluted in
DMEM or purified protein extracted from 4-week QA-lesioned or vehicle
rats (30 μg in 1 ml of culture medium) were incubated in the lower
compartment of 12-well (12 μm pores) or 48-well (8 μm pores) chemotaxis
chambers for rMSCs and rNSCs, respectively (Costar, USA). Assays
were performed in the presence or the absence of a c-kit blocking antibody
(5 ng/ml; rat anti-mouse CD117 c-kit monoclonal antibody clone ACK45,
Pharmingen, Belgium), added to cells 30 min prior to the addition of
recombinant SCF or protein extracts. A total of 106 cells/ml of DMEM
per well (n=12 per condition) was plated in the upper half of the cham-
ber. Cells were separated from the chemoattractant by a polyvinylpyrro-
lidone-free polycarbonate filter. The chambers were incubated in a
humidified incubator containing 5% CO2 for 24 h at 37 °C. Cells which
migrated through the pores were counted in five random squares per well.
It is worth noting that in our paradigm, in order to avoid interference
with other substances, the medium used for testing was DMEM only,
explaining why rMSCs did not re-attach and rNSCs did not form spheres
once they had passed through the micropores (see Supplemental data 4).
Results were expressed as the mean±SEM of the values obtained in
these fields.Proliferation assay
Cell proliferation was measured using an MTS (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, in-
ner salt) reduction assay (Aqueous One Solution cell proliferation assay,
Promega, Belgium). MTS reduction is an indicator of cell number. Brief-
ly, 2.5×104 rMSCs or rNSCs were seeded (n=6 per condition) into each
well of 6-well culture plates with 2.5 ml of culture medium supplemented
with 10 ng/ml recombinant rat SCF (PeproTech, UK) for five days. Cells
were assessed at day 5 by adding 625 μl of dye solution into each well
followed by incubation for 2 h at 37 °C. The absorbance of the final
solution in each well was then measured at 490 nm with a 96-well plate
reader.
Statistics
Results were expressed as means±SEM. Comparisons among groups
were made using one-way analysis of variance (ANOVA) followed by an
LSD-Fisher post hoc test, Bonferroni post hoc test or unpaired Student's t-
test using Statistica Software (Statsoft, France).
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